JPMorgan Chase & Co’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-524,184
| Closed | -$787K | – | 6421 |
|
|
2023
Q1 | $787K | Hold |
524,184
| – | – | ﹤0.01% | 3581 |
|
|
2022
Q4 | $524K | Sell |
524,184
-1,564
| -0.3% | -$1.56K | ﹤0.01% | 3715 |
|
|
2022
Q3 | $947K | Sell |
525,748
-174,142
| -25% | -$314K | ﹤0.01% | 3394 |
|
|
2022
Q2 | $2.03M | Sell |
699,890
-13,723
| -2% | -$39.8K | ﹤0.01% | 3000 |
|
|
2022
Q1 | $1.97M | Sell |
713,613
-217,222
| -23% | -$600K | ﹤0.01% | 3180 |
|
|
2021
Q4 | $4.34M | Sell |
930,835
-99,525
| -10% | -$464K | ﹤0.01% | 2683 |
|
|
2021
Q3 | $8.77M | Buy |
1,030,360
+370,949
| +56% | +$3.16M | ﹤0.01% | 2155 |
|
|
2021
Q2 | $10.8M | Buy |
659,411
+4,597
| +0.7% | +$75.4K | ﹤0.01% | 2083 |
|
|
2021
Q1 | $14.5M | Buy |
654,814
+194,667
| +42% | +$4.3M | ﹤0.01% | 1835 |
|
|
2020
Q4 | $14.2M | Buy |
460,147
+196,273
| +74% | +$6.07M | ﹤0.01% | 1683 |
|
|
2020
Q3 | $5.11M | Buy |
263,874
+18,315
| +7% | +$354K | ﹤0.01% | 2196 |
|
|
2020
Q2 | $3.77M | Buy |
245,559
+20,058
| +9% | +$308K | ﹤0.01% | 2328 |
|
|
2020
Q1 | $1.75M | Buy |
225,501
+18,197
| +9% | +$141K | ﹤0.01% | 2674 |
|
|
2019
Q4 | $2.96M | Buy |
207,304
+5,288
| +3% | +$75.5K | ﹤0.01% | 2481 |
|
|
2019
Q3 | $3.04M | Buy |
202,016
+9,679
| +5% | +$145K | ﹤0.01% | 2504 |
|
|
2019
Q2 | $2.79M | Sell |
192,337
-6,384
| -3% | -$92.5K | ﹤0.01% | 2481 |
|
|
2019
Q1 | $3.46M | Buy |
+198,721
| New | +$3.46M | ﹤0.01% | 2323 |
|